<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137909">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01960881</url>
  </required_header>
  <id_info>
    <org_study_id>P14-096</org_study_id>
    <nct_id>NCT01960881</nct_id>
  </id_info>
  <brief_title>Evaluation of Diet and Exercise in Prostate Cancer Patients</brief_title>
  <acronym>CRONOS II</acronym>
  <official_title>Canadian Real Life Evaluation of Exercise and Diet in Patients Treated With Lupron® for the Management of Prostate Cancer:(CRONOS II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CMX Research Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>JSS Medical Research Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Canadian Real Life Evaluation of the Effect of Diet and Exercise in Prostate Cancer Patients
      Managed with Lupron.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study utilizing a prospective cohort design. Patients with Prostrate cancer (PCa)
      who are prescribed Lupron will be entered into the study cohort and will be followed for a
      maximum of 36 months with recommended assessments at 3, 6, 12, 18, 24, 30 and 36 months
      after Day 1. Treatment of the patients and follow up will be according to the physicians'
      judgment, regional regulations and the product monograph.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Changes in the patient quality of life (QoL) using the Medical Outcomes Study Short Form - 36 (SF-36)</measure>
    <time_frame>From Month 0 to Month 36</time_frame>
    <safety_issue>No</safety_issue>
    <description>The SF-36 Health is a 36-item general health self-administered questionnaire consisting of 8 scales measuring Physical Function, Physical Role limitations, Vitality, General Health, Pain, Social Function, Emotional Role limitations, and Mental Health.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the University of California Los Angeles Prostate Cancer Index (UCLA-PI)</measure>
    <time_frame>From Month 0 to Month 36</time_frame>
    <safety_issue>No</safety_issue>
    <description>A validated questionnaire designed to measure quality of life in patients with prostate cancer. It consists of 20 questions that assess urinary, sexual, bowel and hormonal function and impairment in patients with prostate cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the sexual function using the International Index of Erectile Function (IIEF-5)</measure>
    <time_frame>From Month 0 to Month 36</time_frame>
    <safety_issue>No</safety_issue>
    <description>An abridged 5 item self-administered questionnaire assessing the presence and severity of erectile dysfunction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the proportion of patients with castrate levels of testosterone and normal levels of Prostatic Specific Antigen (PSA) at 36 months of treatments.</measure>
    <time_frame>From Month 0 to Month 36</time_frame>
    <safety_issue>No</safety_issue>
    <description>The PSA test measures the level of PSA in a man's blood. For this test, a blood sample is sent to a laboratory for analysis. The results are usually reported as nanograms of PSA per milliliter (ng/mL) of blood. A testosterone test checks the level of this male hormone (androgen) in the blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Adverse Events</measure>
    <time_frame>From Month 0 to Month 36</time_frame>
    <safety_issue>No</safety_issue>
    <description>Adverse events which lead to discontinuation of prescribed treatment under observation, will be coded according to the Medical Dictionary for Regulatory Activities (MeDRA) dictionary of terms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the patient's medical condition</measure>
    <time_frame>From Month 0 to Month 36</time_frame>
    <safety_issue>No</safety_issue>
    <description>Any change in the patient's medical condition including new onset or worsening of medical conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Doctor-Patient communication</measure>
    <time_frame>From Month 0 to Month 36</time_frame>
    <safety_issue>No</safety_issue>
    <description>This will be ascertained with the Doctor-Patient Communication/Doctor's Questionnaire and the Doctor-Patient Communication/Patient's Questionnaire that are validated questionnaires developed by the College of Physicians of Quebec</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">860</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Prostate Cancer Patients</arm_group_label>
    <description>Prostate Cancer Patients</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be enrolled from the offices of University or community
        urologists/radio-oncologists across Canada treating patients with PCa
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        i. Adult ≥ 18 years old

        ii. Has provided written informed consent allowing the use of their data for the study and
        providing permission for contact by the study personnel.

        iii. Diagnosed with PCa.

        iv. Prescribed Lupron as part of his treatment by his treating physician.

        Exclusion Criteria:

        i. Patient cannot or will not sign informed consent.

        ii. Presence of other condition that, in the opinion of the treating physician, prohibits
        the patient from participating in the study or obscures the assessment of the treatment of
        PCa.

        iii. Survival expectancy less than 2-3 years as per the treating physician judgment

        iv. No longer than 6 months of therapy if currently on Luteinizing hormone-releasing
        hormone (LHRH) agonist treatment.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda  Assouline, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacinthe  Lemay, PhD</last_name>
    <phone>514-832-7321</phone>
    <email>jacinthe.lemay@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Suzanne  Lemay, BS</last_name>
    <phone>888-703-3006 ext 7494</phone>
    <email>suzanne.lemay@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116040</name>
      <address>
        <city>Abbottsford</city>
        <zip>V2S 3N5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116040</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116042</name>
      <address>
        <city>Barrie</city>
        <zip>L4M 7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116042</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 124295</name>
      <address>
        <city>Barrie</city>
        <zip>L4M 7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 124295</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 120695</name>
      <address>
        <city>Belleville</city>
        <zip>K8P 3Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 120695</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116023</name>
      <address>
        <city>Brampton</city>
        <zip>L6T 4S5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116023</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116026</name>
      <address>
        <city>Brantford</city>
        <zip>N8S 6T6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116026</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116035</name>
      <address>
        <city>Burlington</city>
        <zip>L7S 1V2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116035</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116024</name>
      <address>
        <city>Burlington</city>
        <zip>L7N 3V2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116024</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116019</name>
      <address>
        <city>Chicoutimi</city>
        <zip>G7H 4J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116019</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116036</name>
      <address>
        <city>Greenfield Park</city>
        <zip>J4V 2H3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116036</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 124296</name>
      <address>
        <city>Greenfield Park</city>
        <zip>J4V 2H2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 124296</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 118941</name>
      <address>
        <city>Halifax</city>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 118941</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116025</name>
      <address>
        <city>Kelowna</city>
        <zip>V1W 4V5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116025</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116037</name>
      <address>
        <city>Laval</city>
        <zip>H7G 2E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116037</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 118940</name>
      <address>
        <city>London</city>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 118940</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 124075</name>
      <address>
        <city>Miramichi</city>
        <zip>E1V 2N5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 124075</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 120416</name>
      <address>
        <city>Montreal</city>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 120416</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116027</name>
      <address>
        <city>Newmarket</city>
        <zip>L3X 1W1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116027</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116022</name>
      <address>
        <city>North York</city>
        <zip>M2J 1V1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116022</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116020</name>
      <address>
        <city>Oakville</city>
        <zip>L6H 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116020</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116041</name>
      <address>
        <city>Peterborough</city>
        <zip>K9H 1T6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116041</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116355</name>
      <address>
        <city>Pointe-Claire</city>
        <zip>H9R 4S3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116355</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116043</name>
      <address>
        <city>Scarborough</city>
        <zip>M1S 4V5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116043</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116038</name>
      <address>
        <city>Scarborough</city>
        <zip>M1S 1T5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116038</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 124275</name>
      <address>
        <city>Sherbrooke</city>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 124275</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116044</name>
      <address>
        <city>Toronto</city>
        <zip>M6A 3B5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116044</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116021</name>
      <address>
        <city>Toronto</city>
        <zip>M6S 4W4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116021</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116356</name>
      <address>
        <city>Trois-Rivieres</city>
        <zip>G9A 3V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116356</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116039</name>
      <address>
        <city>Val d'Or</city>
        <zip>J9P 1W3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116039</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 120415</name>
      <address>
        <city>Victoria</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 120415</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com</url>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 3, 2014</lastchanged_date>
  <firstreceived_date>October 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
